TradeOrgs
  • Stocks
  • Screener
  • Backtest
  • Watchlist
  • Signals
  • Portfolio
  • Insights
  • Connect
Sign in
RELIANCE₹1,304.00▼ 0.70%TCS₹2,093.50▼ 6.61%HDFCBANK₹801.05▲ 6.29%ICICIBANK₹1,411.40▲ 13.64%INFY₹1,047.20▼ 14.35%HINDUNILVR₹2,201.20▲ 5.29%ITC₹289.95▲ 4.68%SBIN₹1,040.00▲ 7.17%BHARTIARTL₹1,910.40▲ 4.73%KOTAKBANK₹396.75▲ 4.13%LT₹4,026.60▲ 1.86%AXISBANK₹1,342.10▲ 6.92%ASIANPAINT₹2,737.80▲ 2.83%MARUTI₹14,366.00▲ 10.13%AAPL$308.63▼ 2.08%MSFT$390.49▼ 11.52%GOOGL$359.91▼ 0.54%AMZN$242.67▼ 5.40%NVDA$194.83▼ 12.56%META$582.90▼ 2.46%TSLA$393.45▼ 7.15%BRK-B$507.78▲ 7.69%JPM$334.47▲ 11.13%V$362.13▲ 14.12%
RELIANCE₹1,304.00▼ 0.70%TCS₹2,093.50▼ 6.61%HDFCBANK₹801.05▲ 6.29%ICICIBANK₹1,411.40▲ 13.64%INFY₹1,047.20▼ 14.35%HINDUNILVR₹2,201.20▲ 5.29%ITC₹289.95▲ 4.68%SBIN₹1,040.00▲ 7.17%BHARTIARTL₹1,910.40▲ 4.73%KOTAKBANK₹396.75▲ 4.13%LT₹4,026.60▲ 1.86%AXISBANK₹1,342.10▲ 6.92%ASIANPAINT₹2,737.80▲ 2.83%MARUTI₹14,366.00▲ 10.13%AAPL$308.63▼ 2.08%MSFT$390.49▼ 11.52%GOOGL$359.91▼ 0.54%AMZN$242.67▼ 5.40%NVDA$194.83▼ 12.56%META$582.90▼ 2.46%TSLA$393.45▼ 7.15%BRK-B$507.78▲ 7.69%JPM$334.47▲ 11.13%V$362.13▲ 14.12%

TradeOrgs shows market information and analyzes your own trading history. It does not place trades and is not investment advice.

Prices and listings are for information only. We are read-only against your broker account.

Technical signals (RSI, MACD, etc.) are educational readouts of public indicators — not recommendations.

Privacy Policy·© 2026 TradeOrgs

← All stocks

🇺🇸AMPH

Amphastar Pharmaceuticals, Inc. - Common Stock

NASDAQ
$19.64
▲ $1.19 (+6.4%)
Live· just now
delayed feed · not for order timing

Price history · 20-day (cyan) / 50-day (purple) avg

as of 02 Jul 2026
H $29.52L $16.65-28.1%
$29.52$26.95$24.37$21.8$19.22$16.65$19.64
RSI (14)
Intraday · 15-minStrong sell-45RSI 35DowntrendMACD Bearishfor day-trading context — not advice

Technical signal

Neutral-5
RSI (14)48
oversold 30overbought 70
Trend
Sideways
MACD
Bullish
Bollinger
Within bands
vs 20-day
below
vs 50-day
below
vs 200-day
below
Support
$18.22
Resistance
$22.00
  • Price is below its 50-day average (medium-term weakness).

Signal backtest · 2025-09-29 → 2026-07-02

Strategy return
-26.2%
Buy & hold
-27.0%
Trades
7
Win rate
0%

$100,000.00 invested would be worth $73,759.71 (-26.2%) · Full backtester →

Hypothetical: go long when the signal turns Buy, exit when it turns Sell. Past indicator behavior is not a prediction — educational only, not advice.

About Amphastar Pharmaceuticals, Inc.· Drug Manufacturers - Specialty & Generic

source: yahoo

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a dry nasal spray used in an emergency for the treatment of severe hypoglycemia; Primatene MIST, an epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Glucagon for injection emergency kit; Enoxaparin, an injectable form of low molecular weight heparin for the prevention and treatment of deep vein thrombosis; and REXTOVY and Naloxone for opioid overdose. The company also provides Cortrosyn, a lyophilized power for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency; Amphadase, a bovine-sourced hyaluronidase injection; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; and emergency syringe products, including atropine, calcium chloride, dextrose, epinephrine, lidocaine, and sodium bicarbonate. In addition, it offers Albuterol sulfate inhalation aerosol for the treatment or prevention of bronchospasm; Iron sucrose injection, an iron replacement product for the treatment of iron deficiency anemia in patients with chronic kidney disease; Teriparatide injection for managing daily osteoporosis therapy; and Ipratropium Bromide HFA inhalation aerosol, an anticholinergic indicated for the maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease. Further, the company provides active pharmaceutical ingredient (API) products, such as Recombinant Human Insulin and porcine insulin API. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
1,976
Headquarters

Fundamentals

source: yahoo
Market cap
$865.98M
P/E
11.8
P/B
1.1
EPS
$1.66
Div yield
—
Profit margin
11.0%
ROE
10.4%
Debt / Equity
0.89
Beta
0.89
52-week range
$16.65 – $31.26
52-week low · $16.6520% of rangehigh · $31.26

Fundamental data is informational only — not investment advice.

Recent news

News sentiment:— Neutral3↑ · 3↓ · 2–
  • BofA cuts ratings on four biopharma stocks over valuation and catalyst concerns▼ Negative
    Investing.com · 29 Jun 2026
  • Update: BofA Securities Downgrades Amphastar Pharmaceuticals to Underperform From Neutral, Cuts Price Target to $20 From $25▼ Negative
    MT Newswires · 29 Jun 2026
  • New Strong Sell Stocks for June 23rd▲ Positive
    Zacks · 23 Jun 2026
  • 1 Healthcare Stock to Consider Right Now and 2 We Brush Off

Educational technical indicators — not investment advice. TradeOrgs does not place trades.

Rancho Cucamonga, United States
www.amphastar.com ↗
— Neutral
StockStory · 12 Jun 2026
  • Amphastar Pharmaceuticals Pivots to Proprietary Drugs, Biosimilars for Growth▲ Positive
    MarketBeat · 10 Jun 2026
  • How The Investment Story For Amphastar Pharmaceuticals (AMPH) Is Evolving Without New Valuation Shifts— Neutral
    Simply Wall St. · 09 Jun 2026
  • Sentiment is a keyword-based read of the headline — a rough signal, not advice.